Evidence map›Paper›PMID 35522720›Full record

ArticleACS chemical neuroscience2022

Caspase-2 Inhibitor Blocks Tau Truncation and Restores Excitatory Neurotransmission in Neurons Modeling FTDP-17 Tauopathy.

Gurpreet Singh, Peng Liu, Katherine R Yao, Jessica M Strasser, Chris Hlynialuk, Kailee Leinonen-Wright, Peter J Teravskis, Jessica M Choquette, Junaid Ikramuddin, Merlin Bresinsky and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Gurpreet SinghDepartment of Medicinal Chemistry, The University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-5878-3154
Peng LiuDepartment of Neurology, The University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-2615-1213
Katherine R YaoDepartment of Neuroscience, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Jessica M StrasserDepartment of Medicinal Chemistry, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Chris HlynialukDepartment of Neurology, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Kailee Leinonen-WrightDepartment of Neurology, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Peter J TeravskisDepartment of Neuroscience, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Jessica M ChoquetteDepartment of Neuroscience, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Junaid IkramuddinDepartment of Neuroscience, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Merlin BresinskyInstitute of Pharmacy, University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany.
Kathryn M NelsonDepartment of Medicinal Chemistry, The University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-8274-2064
Dezhi LiaoDepartment of Neuroscience, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Karen H AsheDepartment of Neurology, The University of Minnesota, Minneapolis, Minnesota 55455, United States.
Michael A WaltersDepartment of Medicinal Chemistry, The University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-5650-9277
Steffen PockesDepartment of Medicinal Chemistry, The University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-2211-9868
University of Minnesota · USUniversity of Regensburg · DE

Funding

Caspase-2 Probe CompoundsR01AG062199 · NIA · UNIVERSITY OF MINNESOTA · PI ASHE, KAREN H, WALTERS, MICHAEL A. · 2019 to 2023
$3.9M
Epidemiology of racial differences in decision making among older adultsR01AG060376 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BOYLE, PATRICIA A · 2018 to 2022
$3.2M
Role of Tau Cleavage and Phosphorylation in TauopathyRF1AG060766 · NIA · UNIVERSITY OF MINNESOTA · PI ASHE, KAREN H · 2018 to 2018
$3.0M
NIA NIH HHS R01 AG060376NIA NIH HHS R01 AG062199NIA NIH HHS RF1 AG060766
6 · The paper itself

Abstract

Synaptic and cognitive deficits mediated by a severe reduction in excitatory neurotransmission caused by a disproportionate accumulation of the neuronal protein tau in dendritic spines is a fundamental mechanism that has been found repeatedly in models of tauopathies, including Alzheimer's disease, Lewy body dementia, frontotemporal dementia, and traumatic brain injury. Synapses thus damaged may contribute to dementia, among the most feared cause of debilitation in the elderly, and currently there are no treatments to repair them. Caspase-2 (Casp2) is an essential component of this pathological cascade. Although it is believed that Casp2 exerts its effects by hydrolyzing tau at aspartate-314, forming Δtau314, it is also possible that a noncatalytic mechanism is involved because catalytically dead Casp2 is biologically active in at least one relevant cellular pathway, that is, autophagy. To decipher whether the pathological effects of Casp2 on synaptic function are due to its catalytic or noncatalytic properties, we discovered and characterized a new Casp2 inhibitor, compound

Indexed as

Frontotemporal DementiaTauopathiesAnimalsCaspase 2Disease Models, AnimalMiceMice, TransgenicNeuronsRatsSynaptic Transmissiontau ProteinsCasp2 protein, mouseCaspase 2tau ProteinsAlzheimer’s diseaseCaspase-2dementianeurodegenerative disorderstauopathies

Identifiers

PMID35522720
PMCPMC9616053
OpenAlexW4229027549

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.